Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response
Panos, Michael, Christophi, George P. , Rodriguez, Moses , Scarisbrick, Isobel A. , Rodriguez, Moses

Biological Chemistry | August 6, 2014 | Volume: 395 | Issue: 9 | Pages: 1063-1073

10.1515/hsz-2014-0141 | PMID 25153387 Get It

Abstract Recent studies provide a functional link between kallikrein 6 (Klk6) and the development and progression of disease in patients with multiple sclerosis (MS) and in its murine models. To evaluate the involvement of additional kallikrein family members, we compared Klk6 expression with four other kallikreins (Klk1, Klk7, Klk8, and Klk10) in the brain and spinal cord of mice infected with Theiler’s murine encephalomyelitis virus, an experimental model of progressive MS. The robust upregulation of Klk6 and Klk8 in the brain during the acute phase of viral encephalitis and in the spinal cord during disease development and progression points to their participation in inflammation, demyelination, and progressive axon degeneration. More limited changes in Klk1, Klk7, and Klk10 were also observed. In addition, Klk1, Klk6, and Klk10 were dynamically regulated in T cells in vitro as a recall response to viral antigen and in activated monocytes, pointing to their activities in the development of adaptive and innate immune function. Together, these results point to overlapping and unique roles for multiple kallikreins in the development and progression of virus-mediated central nervous system inflammatory demyelinating disease, including activities in the development of the adaptive and innate immune response, in demyelination, and in progressive axon degeneration.
Ischemic Cardiomyopathy is Associated With Coronary Plaque Progression and Higher Event Rate in Patients After Cardiac Transplantation
Matsuo, Yoshiki , Matsuzawa, Yasushi , Lennon, Ryan J. , Lerman, Lilach O. , Kushwaha, Sudhir S. , Guddeti, Raviteja , Aoki, Tatsuo , Lerman, Amir

Journal of the American Heart Association | August 6, 2014 | Volume: 3 | Issue: 4 | Pages: No page available

10.1161/jaha.114.001091 | PMID 25095871 Get It

Background Cardiac allograft vasculopathy is the leading cause of graft failure and death in heart transplant ( HT x) recipients; however, the association between the etiology of heart failure (ischemic cardiomyopathy [ ICM ] or non‐ ICM ) that led to HT x and progression of c ardiac allograft vasculopathy , and adverse events after HT x has not been explored. Methods and Results We retrospectively included 165 HT x patients, who were followed‐up with at least 2 virtual histology–intravascular ultrasound examinations after HT x, and grouped them as ICM (n=46) or non‐ ICM (n=119). Coronary artery plaque volume was analyzed using virtual histology–intravascular ultrasound, and cardiovascular event data—a composite of myocardial infarction, hospitalization for heart failure and arrhythmia, revascularization, retransplantation, and death including cardiovascular death—were collected from the medical records of all study subjects. ICM patients had significantly higher plaque volume at both first ( P =0.040) and follow‐up ( P =0.015) intravascular ultrasound examinations. After multivariate adjustment for traditional coronary risk factors, ICM was significantly associated with plaque progression (odds ratio 3.10; CI 1.17 to 9.36; P =0.023). Ten‐year cardiovascular event‐free survival was 50% in ICM patients compared with 84% in non‐ ICM patients (log‐rank test P =0.003). In multivariate Cox proportional hazard analysis, ICM was significantly associated with a higher event rate after HT x (hazard ratio 2.02; 95% CI 1.01 to 4.00; P =0.048). Conclusion Our study demonstrates that ischemic etiology of cardiomyopathy prior to HT x may be independently associated with plaque progression and higher event rate after HT x.
Minimally Invasive Treatment of a Painful Osteolytic Lumbar Lesion Secondary to Epithelioid Hemangioendothelioma
Sebastian, Arjun S. , Adair, Marcus J. , Khan, Mustafa H. , Arndt, Carola A.S., Morris, Jonathan M. , Khan, Mustafa H. , Nassr, Ahmad

Global Spine Journal | August 5, 2014 | Volume: 5 | Issue: 2 | Pages: 135-139

10.1055/s-0034-1387198 | PMID 25844287 Get It

Study Design Case report. Objective Multifocal epithelioid hemangioendothelioma (EHE) of the spine is a rare disorder. We describe a novel, multimodal treatment of a painful osteolytic lumbar lesion secondary to EHE. The minimally invasive treatment results in an excellent patient outcome with decreased morbidity compared to traditional techniques. Methods A previously healthy young adult presented with a painful osteolytic lesion at the L2 vertebrae. Imaging revealed multifocal spinal lesions consistent with a history of EHE. Core needle biopsy confirmed the diagnosis. Preoperative cryoablation of L2 was followed by a staged surgery, which included a partial L2 corpectomy, tumor resection, bone grafting, and vertebral reconstruction using a minimally invasive technique. This treatment was followed by prolonged therapy with interferon and bisphosphonate. Results At 3.5 years’ follow-up, the patient has maintained his vertebral body height, has not required a fusion, and has had no recurrence of disease. Conclusion Multimodal treatment consisting of tumor cryoablation, partial corpectomy, allograft reconstruction of the vertebrae, and adjuvant interferon and bisphosphonate can result in good outcomes for well-contained EHE tumors of the spine.
Localized Delivery of Brain-Derived Neurotrophic Factor-Expressing Mesenchymal Stem Cells Enhances Functional Recovery following Cervical Spinal Cord Injury
Gransee, Heather M. , Zhan, Wen-Zhi, Sieck, Gary C. , Mantilla, Carlos B. , Zhan, Wen‐Zhi, Sieck, Gary , Gransee, Heather M , Mantilla, Carlos B

Journal of Neurotrauma | August 5, 2014 | Volume: 32 | Issue: 3 | Pages: 185-193

10.1089/neu.2014.3464 | PMID 25093762 Get It

Retrospective Evaluation of the Accuracy of Roche AccuChek Inform and Nova StatStrip Glucose Meters when Used on Critically Ill Patients
Karon, Brad S. , Blanshan, Chanse T., Deobald, Gayle R., Wockenfus, Amy M.

Diabetes Technology & Therapeutics | August 5, 2014 | Volume: 16 | Issue: 12 | Pages: 828-832

10.1089/dia.2014.0074 | PMID 25093919 Get It

Background: More stringent accuracy guidelines for hospital-use glucose meters have recently been published, but it remains unclear whether glucose meters can meet these accuracy guidelines when measurement is performed on critically ill patients with fresh whole blood samples. Materials and Methods: We performed a retrospective evaluation of a conventional (Roche Diagnostics [Indianapolis, IN] AccuChek ® Inform) and a newer-generation (Nova Biomedical [Waltham, MA] StatStrip ® ) glucose system by comparing paired (drawn within 5 min of each other) whole blood glucose meter and laboratory serum glucose values obtained from intensive care unit (ICU) patients. We also performed a prospective evaluation of the accuracy of the Nova StatStrip. Results: The median (interquartile range) bias between Roche AccuChek Inform and serum laboratory glucose measurements was 11 (6–18) mg/dL, compared with a median bias between the Nova StatStrip and serum glucose measurements of 1 (−5 to 5) mg/dL. StatStrip met International Organization for Standardization 15197 and Clinical and Laboratory Standards Institute (CLSI) POCT12-A3 accuracy guidelines using both retrospective and prospective datasets. Conclusions: The newer-generation (StatStrip) glucose meter met more stringent CLSI POCT12-A3 accuracy criteria because of reduced bias compared with the previous-generation device. Reduced glucose meter bias led to fewer insulin dosing discrepancies when the insulin dose determined from serum glucose was compared with that determined from the glucose meter value using the institutional glycemic control protocol.
Cellular Immune Response Against Firefly Luciferase After Sleeping Beauty –Mediated Gene Transfer In Vivo
Podetz-Pedersen, Kelly M., Vezys, Vaiva , Somia, Nikunj V., Russell, Stephen J. , McIvor, R. Scott , Russell, Stephen J , Vezys, Vaiva

Human Gene Therapy | August 5, 2014 | Volume: 25 | Issue: 11 | Pages: 955-965

10.1089/hum.2014.048 | PMID 25093708 Get It

The Sleeping Beauty (SB) transposon system has been shown to mediate new gene sequence integration resulting in long-term expression. Here the effectiveness of hyperactive SB100X transposase was tested, and we found that hydrodynamic co-delivery of a firefly luciferase transposon (pT2/CaL) along with SB100X transposase (pCMV-SB100X) resulted in remarkably sustained, high levels of luciferase expression. However, after 4 weeks there was a rapid, animal-by-animal loss of luciferase expression that was not observed in immunodeficient mice. We hypothesized that this sustained, high-level luciferase expression achieved using the SB100X transposase elicits an immune response in pT2/CaL co-administered mice, which was supported by the rapid loss of luciferase expression upon challenge of previously treated animals and in naive animals adoptively transferred with splenocytes from previously treated animals. Specificity of the immune response to luciferase was demonstrated by increased cytokine expression in splenocytes after exposure to luciferase peptide in parallel with MHC I–luciferase peptide tetramer binding. This anti-luciferase immune response observed following continuous, high-level luciferase expression in vivo clearly impacts its use as an in vivo reporter. As both an immunogen and an extremely sensitive reporter, luciferase is also a useful model system for the study of immune responses following in vivo gene transfer and expression.
The Psychological and Physiological Effects of Acute Occupational Stress in New Anesthesiology Residents
Eisenach, John H., Clark, Matthew M. , Johnson, Bruce D. , Kruse, Timothy N., Chantigian, Daniel P. , Carter, Jason R. , Long, Timothy R. , Šprung, Juraj , Shanafelt, Tait D. , Carter, Jason R

Anesthesiology | August 5, 2014 | Volume: 121 | Issue: 4 | Pages: 878-893

10.1097/aln.0000000000000397 | PMID 25093592 Get It

Abstract Background: Occupational stress in resident physicians has profound implications for wellness, professionalism, and patient care. This observational pilot trial measured psychological and physiological stress biomarkers before, during, and after the start of anesthesia residency. Methods: Eighteen physician interns scheduled to begin anesthesia residency were recruited for evaluation at three time points: baseline (collected remotely before residency in June 2013); first-month visit 1 (July); and follow-up visit 2 (residency months 3 to 5, September–November). Validated scales were used to measure stress, anxiety, resilience, and wellness at all three time points. During visits 1 and 2, the authors measured resting heart-rate variability, responses to laboratory mental stress (hemodynamic, catecholamine, cortisol, and interleukin-6), and chronic stress indices (C-reactive protein, 24-h ambulatory heart rate and blood pressure, 24-h urinary cortisol and catecholamines, overnight heart-rate variability). Results: Thirteen interns agreed to participate (72% enrollment). There were seven men and six women, aged 27 to 33 yr. The mean ± SD of all study variables are reported. Conclusion: The novelty of this report is the prospective design in a defined cohort of residents newly exposed to the similar occupational stress of the operating environment. Because of the paucity of literature specific to the measures and stress conditions in this investigation, no data were available to generate a priori definition of primary outcomes and a data analytic plan. These findings will allow power analysis for future design of trials examining occupational stress and stress-reducing interventions. Given the importance of physician burnout in our country, the impact of chronic stress on resident wellness requires further study.
Recurrent rectal cancer causing lumbosacral plexopathy with perineural spread to the spinal nerves and the sciatic nerve: An anatomic explanation
Capek, Stepan , Howe, Benjamin M. , Smyrk, Thomas C. , Amrami, Kimberly K. , Spinner, Robert J. , Dozois, Eric J. , Sullivan, Patrick S.

Clinical Anatomy | August 5, 2014 | Volume: 28 | Issue: 1 | Pages: 136-143

10.1002/ca.22450 | PMID 25090969 Get It

Several groups have reported cases of rectal cancer with carcinomatous involvement of the lumbosacral plexus and sciatic, obturator, pudendal, or spinal nerves. To our best knowledge, clear examples of perineural tumor spread in rectal carcinoma have not yet been described. We retrospectively reviewed clinical data and imaging studies of three patients with primary or recurrent rectal cancer involving the lumbosacral plexus. Imaging studies included MRI and 18FDG PET/CT scans in all (n = 3) patients, histological samples were available in two (n = 2). Imaging studies demonstrated distinct features of tumor spread from the organ to the plexus and beyond in all cases (n = 3), histological specimens demonstrated perineural involvement thus supporting our theory (n = 2). We present these three cases of perineural tumor spread in rectal cancer as a proof of concept. We hypothesize that not only our cases, but other similar reported cases can be explained anatomically by extension of the rectal cancer to the inferior hypogastric plexus with perineural tumor spread to the lumbosacral plexus using the pelvic and sacral splanchnic nerves as conduits. Once the tumor reaches the lumbosacral plexus, it can continue to spread proximally or distally. We believe that perineural spread of colon cancer represents an important, under‐recognized mechanism of recurrence to neighboring major nerves in the pelvis. Clin. Anat. 28:136–143, 2015. © 2014 Wiley Periodicals, Inc.
Systemic Inflammatory Response Elicited by Superantigen Destabilizes T Regulatory Cells, Rendering Them Ineffective during Toxic Shock Syndrome
Tilahun, Ashenafi Y. , Chowdhary, Vaidehi , David, Chella S., Rajagopalan, Govindarajan , Chowdhary, Vaidehi R

The Journal of Immunology | August 5, 2014 | Volume: 193 | Issue: 6 | Pages: 2919-2930

10.4049/jimmunol.1400980 | PMID 25092888 Get It

Abstract Life-threatening infections caused by Staphylococcus aureus, particularly the community-acquired methicillin-resistant strains of S. aureus, continue to pose serious problems. Greater virulence and increased pathogenicity of certain S. aureus strains are attributed to higher prevalence of exotoxins. Of these exotoxins, the superantigens (SAg) are likely most pathogenic because of their ability to rapidly and robustly activate the T cells even in extremely small quantities. Therefore, countering SAg-mediated T cell activation using T regulatory cells (Tregs) might be beneficial in diseases such as toxic shock syndrome (TSS). As the normal numbers of endogenous Tregs in a typical host are insufficient, we hypothesized that increasing the Treg numbers by administration of IL-2/anti–IL-2 Ab immune complexes (IL2C) or by adoptive transfer of ex vivo expanded Tregs might be more effective in countering SAg-mediated immune activation. HLA-DR3 transgenic mice that closely recapitulate human TSS were treated with IL2C to increase endogenous Tregs or received ex vivo expanded Tregs. Subsequently, they were challenged with SAg to induce TSS. Analyses of various parameters reflective of TSS (serum cytokine/chemokine levels, multiple organ pathology, and SAg-induced peripheral T cell expansion) indicated that increasing the Tregs failed to mitigate TSS. On the contrary, serum IFN-γ levels were increased in IL2C-treated mice. Exploration into the reasons behind the lack of protective effect of Tregs revealed IL-17 and IFN-γ–dependent loss of Tregs during TSS. In addition, significant upregulation of glucocorticoid-induced TNFR family-related receptor on conventional T cells during TSS could render them resistant to Treg-mediated suppression, contributing to failure of Treg-mediated immune regulation.
Advance Directives of Patients With High-Risk or Inoperable Aortic Stenosis
Suri, Rakesh M. , Pislaru, Sorin V. , Greason, Kevin L. , Mathew, Verghese, Rihal, Charanjit S. , Mueller, Paul S. , Nkomo, Vuyisile T. , Rihal, Charanjit S. , Sabbah, Michael S.

JAMA Internal Medicine | August 4, 2014 | Volume: 174 | Issue: 9 | Pages: 1516

10.1001/jamainternmed.2014.3453 | PMID 25089358 Get It